Prelude Therapeutics, Inc. (PRLD)
2.90
+0.04
(+1.40%)
USD |
NASDAQ |
Feb 25, 10:32
Prelude Therapeutics Research and Development Expense (Quarterly) : 21.71M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioLife Solutions, Inc. | 2.709M |
| Immunome, Inc. | 49.19M |
| Incyte Corp. | 595.19M |
| Aclaris Therapeutics, Inc. | 13.03M |
| Relay Therapeutics, Inc. | 68.26M |